Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI


Primary Symbol: V.BTI.H Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(2146)
•••
Comment by jdstoxon Apr 13, 2018 12:23am
201 Views
Post# 27877544

RE:RE:RE:RE:RE:Corporate Presentation

RE:RE:RE:RE:RE:Corporate Presentationdigitel, things changed on April 24, 2017, September 21, 2017 and December 4, 2017. Plans, studies, objectives, all of it.

The word "confidence" as expressed in the MD&A wasn't necessary, in my opinion. The presence of Day, Rathjen, Radhakrishnan, Stagliano, Hill and the other 13 faces in the corporate presentation express all the confidence in Bioasis that I need.

You can keep on asking for survival data, digitel. I can give you some places to start looking for it. The observation deck at the Empire State Building, Cave of the Evil Spirits at Niagara Falls, Club 33 at Disneyland, the third whirling dervishes' tent on the eastern approaches of Canakkale, maybe the large safe in the office of the Coca Cola CEO where the Coke formula is kept.

Happy hunting, digitel.

jdstox

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities